LLY

1,064.63

+0.2%↑

JNJ

208.64

-0.99%↓

ABBV

227.15

+0.59%↑

UNH

332.67

+1.59%↑

AZN

91.36

+0.93%↑

LLY

1,064.63

+0.2%↑

JNJ

208.64

-0.99%↓

ABBV

227.15

+0.59%↑

UNH

332.67

+1.59%↑

AZN

91.36

+0.93%↑

LLY

1,064.63

+0.2%↑

JNJ

208.64

-0.99%↓

ABBV

227.15

+0.59%↑

UNH

332.67

+1.59%↑

AZN

91.36

+0.93%↑

LLY

1,064.63

+0.2%↑

JNJ

208.64

-0.99%↓

ABBV

227.15

+0.59%↑

UNH

332.67

+1.59%↑

AZN

91.36

+0.93%↑

LLY

1,064.63

+0.2%↑

JNJ

208.64

-0.99%↓

ABBV

227.15

+0.59%↑

UNH

332.67

+1.59%↑

AZN

91.36

+0.93%↑

Search

Nektar Therapeutics

Chiusa

43.94 -2.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

42.59

Massimo

45.99

Metriche Chiave

By Trading Economics

Entrata

6.1M

-36M

Vendite

615K

12M

EPS

-1.87

Margine di Profitto

-301.289

Dipendenti

61

EBITDA

6.9M

-29M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+128.66% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-55M

1.1B

Apertura precedente

46.9

Chiusura precedente

43.94

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Nektar Therapeutics Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 dic 2025, 23:54 UTC

Azioni calde

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Utili

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

I principali Market Mover

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Utili

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Discorsi di Mercato

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Discorsi di Mercato
Utili

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Acquisizioni, Fusioni, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Utili

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Greater China Rev $1.42B >NKE

Confronto tra pari

Modifica del prezzo

Nektar Therapeutics Previsione

Obiettivo di Prezzo

By TipRanks

128.66% in crescita

Previsioni per 12 mesi

Media 103.88 USD  128.66%

Alto 135 USD

Basso 30 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Nektar Therapeutics - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

7

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.5949 / 0.7406Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat